1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Fatty Acid Synthase (FASN)

Fatty Acid Synthase (FASN)

Fatty Acid Synthase (FASN) is a multifunctional homodimeric enzyme protein, and it is the major enzyme required for the anabolic conversion of dietary carbohydrates to fatty acids. Fatty acid synthase catalyzes the conversion of acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids.

Human fatty acid synthase is a large homodimeric multifunctional enzyme that synthesizes palmitic acid. The unique carboxyl terminal thioesterase domain of fatty acid synthase hydrolyzes the growing fatty acid chain and plays a critical role in regulating the chain length of fatty acid released. Also, the up-regulation of human fatty acid synthase in a variety of cancer makes the thioesterase a candidate target for therapeutic treatment.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-U00436
    FASN-IN-3
    Inhibitor 98.06%
    FASN-IN-3 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A.
    FASN-IN-3
  • HY-RS04754
    Fasn Mouse Pre-designed siRNA Set A
    Inhibitor

    Fasn Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fasn gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Fasn Mouse Pre-designed siRNA Set A
    Fasn Mouse Pre-designed siRNA Set A
  • HY-E70265
    18:0 Coenzyme A triammonium
    ≥99.0%
    18:0 Coenzyme A (triammonium) is a preferred substrate of stearoyl-CoA desaturases (SCDs).
    18:0 Coenzyme A triammonium
  • HY-N0082
    Praeruptorin B
    Inhibitor 99.95%
    Praeruptorin B is an inhibitor of sterol regulatory element-binding proteins (SREBPs).
    Praeruptorin B
  • HY-117769
    GSK837149A
    Inhibitor ≥99.0%
    GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on FASN and selectivity for type I FASN (Ki=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer.
    GSK837149A
  • HY-12648
    FASN-IN-4
    Inhibitor 99.21%
    FASN-IN-4 is a potent inhibitor of fatty acid synthase (FASN) with an IC50 of 10 nM (WO2012064642A1, compound 29). FASN-IN-4 also inhibits SARS-CoV-2 with an EC50 of 18.6 nM.
    FASN-IN-4
  • HY-128851A
    Coenzyme A trilithium
    Chemical
    Coenzyme A (CoASH) is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids.
    Coenzyme A trilithium
  • HY-B0218S
    Orlistat-d3
    Inhibitor
    Orlistat-d3 is a deuterated labeled Orlistat. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity.?Anti-atherosclerotic?effect.
    Orlistat-d<sub>3</sub>
  • HY-128851R
    Coenzyme A (Standard)
    Chemical
    Coenzyme A (Standard) is the analytical standard of Coenzyme A. This product is intended for research and analytical applications. Coenzyme A (CoASH) is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids[1].
    Coenzyme A (Standard)
  • HY-P99133
    Anti-Mouse Fas Ligand Antibody (MFL3)
    Inhibitor
    Anti-Mouse Fas Ligand Antibody is an anti-mouse Fas Ligand IgG antibody inhibitor derived from host Armenian Hamster.
    Anti-Mouse Fas Ligand Antibody (MFL3)
  • HY-170570
    PFM046
    Inhibitor
    PFM046 is the antagonist for liver X receptor (LXR), that inhibits the activation of LXRα and LXRβ with IC50 of 2.04 μM and 1.58 μM. PFM046 inhibits the expression of SCD1 and FASN, upregulates the expression of ABCA1, and exhibits antitumor efficacy in mouse models.
    PFM046
  • HY-N0686R
    Pseudoprotodioscin (Standard)
    Inhibitor
    Pseudoprotodioscin (Standard) is the analytical standard of Pseudoprotodioscin. This product is intended for research and analytical applications. Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides.
    Pseudoprotodioscin (Standard)
  • HY-N2486R
    Desoxyrhaponticin (Standard)
    Inhibitor
    Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.
    Desoxyrhaponticin (Standard)
  • HY-167879
    (Rac)-NPD6433
    Inhibitor
    (Rac)-NPD6433 is a racemate of NPD6433. NPD6433 is a triazenyl indole with broad-spectrum activity against all screening fungal strains. NPD6433 targets the enoyl reductase domain of fatty acid synthase 1 (Fas1), covalently inhibiting its flavin mononucleotide-dependent NADPH-oxidation activity and arresting essential fatty acid biosynthesis.
    (Rac)-NPD6433
  • HY-149540
    CTL-06
    Inhibitor
    CTL-06 is an inhibitor of Fatty Acid Synthase (FASN) (IC50: 3 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research.
    CTL-06
  • HY-N0083R
    Betulin (Standard)
    Inhibitor
    Betulin (Standard) is the analytical standard of Betulin. This product is intended for research and analytical applications. Betulin (Trochol), is a sterol regulatory element-binding protein (SREBP) inhibitor with an IC50 of 14.5 μM in K562 cell line.
    Betulin (Standard)
  • HY-P10227
    Xelafaslatide
    Inhibitor
    Xelafaslatide is a Fatty acid synthase (Fas) receptor antagonist.
    Xelafaslatide
  • HY-149545
    1,3-Palmitin-2-docosahexaenoin
    Inhibitor
    1,3-Palmitin-2-docosahexaenoin (1,3-Dipalmitoyl-2-docosahexaenoyl glycerol) is the isomer of triacylglycerol (TAG), in which docosahexaenoic acid (DHA) is located at the β position (sn-2) of the glycerol backbone. 1,3-Palmitin-2-docosahexaenoin inhibits fatty acid synthase and cholesterol metabolism enzymes, activates carnitine palmitoyltransferase (CPT) in liver mitochondria and promotes β-oxidation of fatty acids. 1,3-Palmitin-2-docosahexaenoin exhibits lipid metabolism regulating activity.
    1,3-Palmitin-2-docosahexaenoin
  • HY-13447
    PF-429242
    Inhibitor
    PF429242 is a reversible and competitive SREBP site 1 protease (S1P) inhibitor with an IC50 of 175 nM.
    PF-429242
  • HY-155282
    FASN-IN-6
    Inhibitor
    FASN-IN-6 (compound 44) is a potent fatty acid biosynthesis (FAB) inhibitor. FASN-IN-6 is an antibacterial agent with MICs of 1 μg/mL and 4 μg/mL for S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively.
    FASN-IN-6
Cat. No. Product Name / Synonyms Application Reactivity